Serum IgA proteomics reveals clonal composition and neutralization of dimeric and monomeric IgA repertoires against human norovirus
Juyeon Park, Gyunghee Jo, Yaoska Reyes, Whitney Pickens, Dae Sung Kim, Alexandra Beaver, Verónica P. Costantini, Chang Liu, Daeun Kim, Daechan Park, Victoria Longo, Paul D. Brewer-Jensen, Michael L. Mallory, Ed Satterwhite, Rocio Zapata-Bustos, Jeffrey Marchioni, Mark R. Zweigart, Becca A. Flitter, Jan Vinjé, Julianna Han, Ted M. Ross, Jiwon Lee, Jason J. Lavinder, Sean N. Tucker, Zunlong Ke, Andrew B. Ward, Lisa C. Lindesmith, Ralph S. Baric, George GeorgiouProtection against human norovirus correlates with attachment ligand blockade antibody titers, fecal IgA titers, and serum IgA titers. IgA responses in serum comprise approximately 80 to 95% of monomeric IgA (mIgA) and 5 to 20% of dimeric IgA (dIgA). Using serum LC–MS/MS proteomics, we established clonal relationships between circulating IgG and IgA, as well as between dIgA and mIgA. We observed a modest degree of clonal overlap between circulating IgG and IgA at steady state and found that more than 80% of antigen-specific mIgA was also detectable as dIgA. We biochemically characterized neutralizing epitopes on norovirus GII.4 virus-like particles (VLPs) targeted by serum IgA clonotypes and demonstrated that dIgA markedly enhances neutralization potency relative to mIgA and IgG in an epitope-specific manner. Cryoelectron microscopy and cryoelectron tomography revealed that whether IgA dimerization enhances viral neutralization depends on epitope accessibility on the VLP and antibody binding orientation. Together, these findings provide molecular-level resolution of the serum IgA response and define the structural basis by which dIgA enhances neutralization potency in an epitope-specific manner.